Ying Zhou1, Rong Yan1, Guo Qing Ru2, Li Li Yu2, Jiong Yao3, Hong Wang4. 1. Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital Hang Zhou Medical College, Zhejiang, China. 2. Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital Hang Zhou Medical College, Zhejiang, China. 3. Department of Medical Record Statistic Information, Zhejiang Provincial People's Hospital, People's Hospital Hang Zhou Medical College, Zhejiang, China. 4. Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital Hang Zhou Medical College, Zhejiang, China. hongwang71@yahoo.com.
Abstract
BACKGROUND: The safety of nucleos(t)ide analogue (NA) treatment cessation remains one of the most controversial topics in the management of chronic hepatitis B (CHB) patients. This study investigated the efficiency of 48-week pegylated-interferon (peg-IFN) alfa-2a consolidation therapy on viral relapse after discontinued NA treatment in CHB patients who achieved hepatitis B e antigen (HBeAg) seroconversion for > 1 year. METHODS: NA-treated HBeAg-positive patients who achieved the standard of discontinued NA treatment (i.e. time of HBeAg seroconversion > 1 year) were randomly assigned to receive peg-IFN consolidation (n = 24) treatment or continue original NA therapy (n = 24) for 48 weeks. The treatments were then discontinued, and the patients were observed up to 144 weeks. The primary endpoint was the proportion of patients with viral relapse at week 144 among those who received at least one dose of study drug or had at least one study visit [modified intention-to-treat population (mITT)]. RESULTS: Of the 24 patients who received peg-IFN treatment, 6 (25%) experienced viral relapse and 8 (36.3%) showed HBsAg loss during 96 weeks of treatment-free follow-up. Of the patients who underwent NA consolidation treatment, only 1 (4.3%) of 23 patients showed HBsAg loss and 14 (58.3%) of 24 patients experienced viral relapse during follow-up. HBsAg level decline < 0.25 log10 IU/mL at week 96 was significantly associated with viral relapse. CONCLUSION: A 48-week peg-IFN alfa-2a consolidation therapy increased the rate of HBsAg loss and sustained viral replication suppression in HBeAg-positive patients who achieved HBeAg seroconversion for > 1 year after NA treatment discontinuation.
BACKGROUND: The safety of nucleos(t)ide analogue (NA) treatment cessation remains one of the most controversial topics in the management of chronic hepatitis B (CHB) patients. This study investigated the efficiency of 48-week pegylated-interferon (peg-IFN) alfa-2a consolidation therapy on viral relapse after discontinued NA treatment in CHB patients who achieved hepatitis B e antigen (HBeAg) seroconversion for > 1 year. METHODS: NA-treated HBeAg-positive patients who achieved the standard of discontinued NA treatment (i.e. time of HBeAg seroconversion > 1 year) were randomly assigned to receive peg-IFN consolidation (n = 24) treatment or continue original NA therapy (n = 24) for 48 weeks. The treatments were then discontinued, and the patients were observed up to 144 weeks. The primary endpoint was the proportion of patients with viral relapse at week 144 among those who received at least one dose of study drug or had at least one study visit [modified intention-to-treat population (mITT)]. RESULTS: Of the 24 patients who received peg-IFN treatment, 6 (25%) experienced viral relapse and 8 (36.3%) showed HBsAg loss during 96 weeks of treatment-free follow-up. Of the patients who underwent NA consolidation treatment, only 1 (4.3%) of 23 patients showed HBsAg loss and 14 (58.3%) of 24 patients experienced viral relapse during follow-up. HBsAg level decline < 0.25 log10 IU/mL at week 96 was significantly associated with viral relapse. CONCLUSION: A 48-week peg-IFN alfa-2a consolidation therapy increased the rate of HBsAg loss and sustained viral replication suppression in HBeAg-positive patients who achieved HBeAg seroconversion for > 1 year after NA treatment discontinuation.
Entities:
Keywords:
Antivirus; Hepatitis B surface antigen; Hepatitis B virus; Pegylated-interferon alfa-2a
Authors: Erik H C J Buster; Hajo J Flink; Yilmaz Cakaloglu; Krzysztof Simon; Jörg Trojan; Fehmi Tabak; Thomas M K So; S Victor Feinman; Tomasz Mach; Ulus S Akarca; Martin Schutten; Wanda Tielemans; Anneke J van Vuuren; Bettina E Hansen; Harry L A Janssen Journal: Gastroenterology Date: 2008-05-15 Impact factor: 22.682
Authors: Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad Journal: Hepatology Date: 2015-11-13 Impact factor: 17.425
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Man-Fung Yuen; Danny Ka-Ho Wong; James Fung; Philip Ip; David But; Ivan Hung; Kevin Lau; John Chi-Hang Yuen; Ching-Lung Lai Journal: Gastroenterology Date: 2008-07-16 Impact factor: 22.682
Authors: Sylvia M Brakenhoff; Robert A de Man; André Boonstra; Margo J H van Campenhout; Robert J de Knegt; Florian van Bömmel; Annemiek A van der Eijk; Thomas Berg; Bettina E Hansen; Harry L A Janssen; Milan J Sonneveld Journal: Aliment Pharmacol Ther Date: 2020-11-21 Impact factor: 8.171